Botulinum toxin type B for treatment of spasmodic dysphonia: A case report

Robert Thayer Sataloff; Yolanda D. Heman-Ackah; Lance L. Simpson; Jong Beak Park; Amy Zwislewski; Caren Sokolow; Steven Mandel

doi:10.1016/S0892-1997(02)00114-5

Botulinum toxin type B for treatment of spasmodic dysphonia: A case report

Robert Thayer Sataloff, Yolanda D. Heman-Ackah, Lance L. Simpson, Jong Beak Park, Amy Zwislewski, Caren Sokolow, Steven Mandel

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.

Original language	English (US)
Pages (from-to)	422-424
Number of pages	3
Journal	Journal of Voice
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/S0892-1997(02)00114-5
State	Published - 2002
Externally published	Yes

Keywords

Botulinum toxin
Botulinum toxin B
Laryngeal dystonia
Spasmodic dysphonia

ASJC Scopus subject areas

Speech and Hearing
LPN and LVN
Otorhinolaryngology

Access to Document

10.1016/S0892-1997(02)00114-5

Cite this

@article{9520a236dc0c4d6b8fc90f4d4667dfaa,

title = "Botulinum toxin type B for treatment of spasmodic dysphonia: A case report",

abstract = "Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.",

keywords = "Botulinum toxin, Botulinum toxin B, Laryngeal dystonia, Spasmodic dysphonia",

author = "Sataloff, {Robert Thayer} and Heman-Ackah, {Yolanda D.} and Simpson, {Lance L.} and Park, {Jong Beak} and Amy Zwislewski and Caren Sokolow and Steven Mandel",

year = "2002",

doi = "10.1016/S0892-1997(02)00114-5",

language = "English (US)",

volume = "16",

pages = "422--424",

journal = "Journal of Voice",

issn = "0892-1997",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - Botulinum toxin type B for treatment of spasmodic dysphonia

T2 - A case report

AU - Sataloff, Robert Thayer

AU - Heman-Ackah, Yolanda D.

AU - Simpson, Lance L.

AU - Park, Jong Beak

AU - Zwislewski, Amy

AU - Sokolow, Caren

AU - Mandel, Steven

PY - 2002

Y1 - 2002

N2 - Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.

AB - Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.

KW - Botulinum toxin

KW - Botulinum toxin B

KW - Laryngeal dystonia

KW - Spasmodic dysphonia

UR - http://www.scopus.com/inward/record.url?scp=0036727670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036727670&partnerID=8YFLogxK

U2 - 10.1016/S0892-1997(02)00114-5

DO - 10.1016/S0892-1997(02)00114-5

M3 - Article

C2 - 12395995

AN - SCOPUS:0036727670

SN - 0892-1997

VL - 16

SP - 422

EP - 424

JO - Journal of Voice

JF - Journal of Voice

IS - 3

ER -

Botulinum toxin type B for treatment of spasmodic dysphonia: A case report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this